Chronic obstructive pulmonary disease (COPD) is characterized by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and lungs. The major risk factors are cigarette smoking and exposure to occupational dusts and chemicals. Clinically, COPD most commonly presents with exertional dyspnea, chronic cough, and sputum production that typically worsens over time. Pathologically, COPD involves chronic inflammation in the airways and lung parenchyma, along with the destruction of lung tissue seen in emphysema.
Bronchial Asthma: Definition,Pathophysiology and ManagementMarko Makram
Definition and Pathophysiology of Asthma in addition to classification and recent updates in the management of asthma based on GINA-2019 Guidelines, by Dr. Marco Makram.
Bronchial Asthma: Definition,Pathophysiology and ManagementMarko Makram
Definition and Pathophysiology of Asthma in addition to classification and recent updates in the management of asthma based on GINA-2019 Guidelines, by Dr. Marco Makram.
Etiopathogenesis and pharmacotherapy of COPD
a. the pathophysiology of selected disease states and the rationale for drug therapy;
b. the therapeutic approach to management of these diseases;
c. the controversies in drug therapy;
d. the importance of preparation of individualised therapeutic plans based on diagnosis;
e. needs to identify the patient-specific parameters relevant in initiating drug therapy,
and monitoring therapy (including alternatives, time-course of clinical and laboratory
indices of therapeutic response and adverse effects);
f. describe the pathophysiology of selected disease states and explain the rationale for
drug therapy;
g. summarise the therapeutic approach to management of these diseases including
reference to the latest available evidence;
h. discuss the controversies in drug therapy;
i. discuss the preparation of individualised therapeutic plans based on diagnosis; and
j. identify the patient-specific parameters relevant in initiating drug therapy, and
monitoring therapy (including alternatives, time-course of clinical and laboratory
indices of therapeutic response and adverse effects).
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
One of the most developed cities of India, the city of Chennai is the capital of Tamilnadu and many people from different parts of India come here to earn their bread and butter. Being a metropolitan, the city is filled with towering building and beaches but the sad part as with almost every Indian city
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
How many patients does case series should have In comparison to case reports.pdfpubrica101
Pubrica’s team of researchers and writers create scientific and medical research articles, which may be important resources for authors and practitioners. Pubrica medical writers assist you in creating and revising the introduction by alerting the reader to gaps in the chosen study subject. Our professionals understand the order in which the hypothesis topic is followed by the broad subject, the issue, and the backdrop.
https://pubrica.com/academy/case-study-or-series/how-many-patients-does-case-series-should-have-in-comparison-to-case-reports/
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
The Importance of Community Nursing Care.pdfAD Healthcare
NDIS and Community 24/7 Nursing Care is a specific type of support that may be provided under the NDIS for individuals with complex medical needs who require ongoing nursing care in a community setting, such as their home or a supported accommodation facility.
2. COPD - Definition
Global Obstructive Lung Disease Guidelines (GOLD) : 2013
• “A common preventable and treatable disease state
characterized by persistent airflow limitation that is
usually progressive and associated with enhanced
chronic inflammatory response in the airways and the lung
to noxious particles or gasses. “
• GOLD guidelines were recently updated in 2013
3. Extrapulmonary effects : skeletal muscle
wasting, cachexia
Comorbidities: cardiovascular (ischemic heart
disease and heart failure), osteoporosis ,
normocytic anemia, diabetes, metabolic
syndrome and depression, musculoskeletal and
psychological conditions
Chronic obstructive pulmonary disease (COPD)
encompasses several diffuse pulmonary diseases,
including chronic bronchitis, emphysema, chronic
asthma, bronchiectasis, and:
The result is irreversible airflow obstruction.
4.
5. Chronic bronchitis (definition): — Chronic bronchitis is
defined as a chronic productive cough for three months in
each of two successive years in a patient in whom other
causes of chronic cough (eg, bronchiectasis) have been
excluded. It may precede or follow development of
airflow limitation. This definition has been used in many
studies, despite the arbitrarily selected symptom duration.
6. Chronic bronchitis can be categorized as:
1.Non-obstructive chronic bronchitis:
a) simple chronic bronchitis - (mucoid sputum production characterizes
simple chronic bronchitis),
b) chronic mucopurulent bronchitis - (persistent or recurrent purulent
sputum production in the absence of localized suppurative disease, such as
bronchiectasis, characterizes chronic mucopurulent bronchitis).
2. Obstructive chronic bronchitis (chronic bronchitis with obstruction).
Chronic bronchitis with obstruction must be distinguished from chronic infective
asthma. The differentiation is based mainly on the history of the clinical
illness:
• patients who have chronic bronchitis with obstruction present with a
long history of productive cough and a late onset of wheezing, whereas
•patients who have asthma with chronic obstruction have a long history of
wheezing with a late onset of productive cough.
7. Emphysema — Emphysema is defined by abnormal and
permanent enlargement of the airspaces distal to the
terminal bronchioles that is accompanied by destruction of
the airspace walls, without obvious fibrosis (ie, there is no
fibrosis visible to the naked eye). Exclusion of obvious fibrosis
was intended to distinguish the alveolar destruction due to
emphysema from that due to the interstitial pneumonias, etc.
However, many studies have found increased collagen in the lungs
of patients with mild COPD, indicating that fibrosis can be a
component of emphysema. While emphysema can exist in
individuals who do not have airflow obstruction, it is more common
among patients who have moderate or severe airflow obstruction.
The various subtypes of emphysema (eg, centriacinar,
panacinar, distal acinar (paraseptal) are described
below.
8. Asthma — The Global Initiative for Asthma gives the following definition
of asthma.
“Asthma is a chronic inflammatory disorder of the airways in
which many cells and cellular elements play a role.
The chronic inflammation is associated with airway
responsiveness that leads to recurrent episodes of wheezing,
breathlessness, chest tightness, and coughing, particularly at
night or in the early morning. These episodes are usually
associated with widespread, but variable, airflow obstruction
within the lung that is often reversible either spontaneously
or with treatment.”
10. Chronic obstruction as an element, (but not an
essence) of other nosological entities:
•Patients with airflow obstruction due to diseases that have
a known etiology or a specific pathology (eg, cystic fibrosis,
bronchiectasis, obliterative bronchiolitis, tuberculosis) are not
considered to have COPD. However, these exclusions are
loosely defined.
11. PATHOLOGY — The predominant pathologic
changes of COPD are found in the airways, but
changes are also seen in the lung parenchyma and
pulmonary vasculature.
In an individual, the pattern of pathologic changes
depends on the underlying disease (eg, chronic
bronchitis, emphysema, alpha-1 antitrypsin
deficiency), possibly individual susceptibility, and
disease severity.
12. Airways — Airways abnormalities in COPD include chronic
inflammation, increased numbers of goblet cells, mucus gland
hyperplasia, fibrosis, narrowing and reduction in the number of
small airways, and airway collapse due to the loss of tethering
caused by alveolar wall destruction in emphysema.
•Chronic inflammation in chronic bronchitis and emphysema is
characterized by the presence of CD8+ T-lymphocytes, neutrophils,
and CD68+ monocytes/macrophages in the airways. Among patients
with chronic bronchitis who have mucus hypersecretion, an
increased number of goblet cells and enlarged submucosal glands
are typically seen.
•In comparison, the bronchial inflammation of asthma is
characterized by the presence of CD4+ T-lymphocytes, eosinophils,
and increased interleukin (IL)-4 and IL-5.
13. Lung parenchyma — Emphysema affects the structures distal to the terminal
bronchiole, consisting of the respiratory bronchiole, alveolar ducts, alveolar
sacs, and alveoli, known collectively as the acinus. These structures in
combination with their associated capillaries and interstitium form the lung
parenchyma. The part of the acinus that is affected by permanent dilation or
destruction determines the subtype of emphysema.
•Proximal acinar (also known as centrilobular) emphysema refers to
abnormal dilation or destruction of the respiratory bronchiole, the central
portion of the acinus. It is commonly associated with cigarette smoking, but
can also be seen in coal workers’ pneumoconiosis.
•Panacinar emphysema refers to enlargement or destruction of all parts of
the acinus. Diffuse panacinar emphysema is most commonly associated with
alpha-1 antitrypsin deficiency, although it can be seen in combination with
proximal emphysema in smokers.
•In distal acinar (also known as paraseptal) emphysema, the
alveolar ducts are predominantly affected. Distal acinar emphysema
may occur alone or in combination with proximal acinar and panacinar
emphysema. When it occurs alone, the usual association is spontaneous
pneumothorax in a young adult.
14. Pulmonary vasculature —
Changes in the pulmonary vasculature include
•intimal hyperplasia and
•smooth muscle hypertrophy/hyperplasia thought to
be due to chronic hypoxic vasoconstriction of the small
pulmonary arteries.
•Destruction of alveoli due to emphysema can lead to
loss of the associated areas of the pulmonary capillary
bed.
15. COPD - Risk FactorsCOPD - Risk Factors
• Hereditary - Alpha-1 Antitrypsin Deficiency
• Environmental
• Cigarette Smoking
• 15-20% of smokers will develop COPD
• (~1 in 5) - this implies a genetic
predisposition to developing COPD; tends
to cluster in families
• Occupational exposures to dust, chemicals
• Hereditary - Alpha-1 Antitrypsin Deficiency
• Environmental
• Cigarette Smoking
• 15-20% of smokers will develop COPD
• (~1 in 5) - this implies a genetic
predisposition to developing COPD; tends
to cluster in families
• Occupational exposures to dust, chemicals
16. CLINICAL FEATURES
Smoking and inhalational exposure history — The most
important risk factor for COPD is cigarette smoking and the amount
and duration of smoking contribute to disease severity. Thus, a key
step in the evaluation of patients with suspected COPD is to ascertain
the number of pack years smoked (packs of cigarettes per day
multiplied by the number of years), as the majority (80 percent) of
patients with COPD have a history of cigarette smoking. It is useful to
ask the age of starting and the age of quitting, as patients may
underestimate the number of years they smoked. With enough
smoking, almost all smokers will develop measurably reduced lung
function. In the absence of
agenetic/environmental/occupational predisposition,
smoking less than 10 to 15 pack years of cigarettes is unlikely
to result in COPD.
Best variable for predicting which adults will have airflow
obstruction on spirometry is a history of more than 40 pack
years of smoking
17. The chronologically
taken environmental/occupational history may
disclose other important risk factors for COPD,
such as exposure to fumes or organic or inorganic
dusts. These exposures help to explain the 20 percent of
patients with COPD (defined by lung function alone) and
the 20 percent of patients who die from COPD who
never smoked
18. Symptoms and pattern of onset —
The three cardinal symptoms of COPD are:
•dyspnea,
•chronic cough and sputum production and the most
common early symptom is
•exertional dyspnea.
•Less common symptoms include
•wheezing and
•chest tightness.
•However, any of these symptoms may develop
independently and with variable intensity.
•There are three typical ways in which patients
with COPD present:
19. 1. Patients who have an extremely sedentary
lifestyle but few complaints require careful
questioning to elicit a history that is suggestive of
COPD. Some patients unknowingly avoid exertional
dyspnea by shifting their expectations and limiting
their activity. They may be unaware of the extent
of their limitations or that their limitations are due
to respiratory symptoms, although they may
complain of fatigue.
20. 2. Patients who present with respiratory
symptoms generally complain of dyspnea and
chronic cough.
The dyspnea may initially be noticed only during
exertion. However, it eventually becomes noticeable
with progressively less exertion or even at rest.
The chronic cough is characterized by the insidious
onset of sputum production, which occurs in the
morning initially, but may progress to occur throughout
the day. The daily volume rarely exceeds 60 mL.
The sputum is usually mucoid, but becomes purulent
during exacerbations.
21. •3. Patients who present with episodes of
increased cough, purulent sputum, wheezing,
and dyspnea that occur intermittently, with or
without fever.
• Diagnosis can be problematic in such patients.
The combination of wheezing plus dyspnea may lead to
an incorrect diagnosis of asthma.
• Conversely, other illnesses with similar manifestations
are often incorrectly diagnosed as a COPD
exacerbation (eg, heart failure, bronchiectasis,
bronchiolitis).
The interval between exacerbations decreases as
the severity of the COPD increases
22. Approximately 62 percent of patients with
moderate to severe COPD report variability in
symptoms (eg, dyspnea, cough, sputum,
wheezing, or chest tightness) over the course of
the day or week-to-week;
morning is typically the worst time of day.
23. SYSTEMIC SYMPTOMS, etc.
Patients with COPD may experience weight gain
(due to activity limitations), weight loss (possibly
due to dyspnea while eating), muscle weakness,
limitation of activity (including sexual), cough
syncope, or feelings of depression or anxiety.
Weight loss, even cachexia (PP-emphysema)
generally reflects more advanced disease and is
associated with a worse prognosis. However, the
majority of COPD patients are overweight or obese
(BB-bronchitis).
24. Comorbid diseases that may accompany
COPD
include lung cancer, coronary heart disease,
osteoporosis, metabolic syndrome, skeletal
muscle weakness, depression, and cognitive
dysfunction. Patients may also report a family
history of COPD or other chronic respiratory
illness.
25. Physical examination — 1
The findings on physical examination of the chest vary with the severity
of the COPD.
•Early in the disease, the physical examination may be normal, or may
show only prolonged expiration or wheezes on forced exhalation.
•As the severity of the airway obstruction increases, physical
examination may reveal hyperinflation (eg, increased resonance
to percussion), decreased breath sounds, wheezes, crackles at the
lung bases, and/or distant heart sounds.
•Features of severe disease include an increased anteroposterior
diameter of the chest (“barrel-shaped” chest) and a depressed
diaphragm with limited movement based on chest percussion.
Yellow nicotine stains on the fingers are a clue to ongoing and
heavy cigarette smoking.
Clubbing of the digits is not typical in COPD (even with
associated hypoxemia) and suggests comorbidities such as lung
cancer, interstitial lung disease, or bronchiectasis.
26. •Patients with end-stage COPD may adopt positions that relieve
dyspnea, such as leaning forward with arms outstretched and
weight supported on the palms or elbows. This posture may be
evident during the examination or may be suggested by the
presence of callouses or swollen bursae on the extensor surfaces
of forearms. Other physical examination findings include use of
the accessory respiratory muscles of the neck and shoulder
girdle, expiration through pursed lips, paradoxical retraction of
the lower interspaces during inspiration (ie, Hoover's sign),
cyanosis, asterixis due to severe hypercapnia, and an enlarged,
tender liver due to right heart failure. Neck vein distention may
also be observed because of increased intrathoracic pressure,
especially during expiration.
Physical examination — 2
27. EVALUATION — Evaluation for COPD is
appropriate in adults who report dyspnea, chronic
cough, chronic sputum production or have had a
gradual decline in level of peak activity, particularly if
they have a history of exposure to risk factors for the
disease (eg, cigarette smoking, indoor biomass
smoke). All patients are evaluated with spirometry
and selected patients have laboratory testing and
imaging studies.
28. COPD - Prevalence
• Fourth leading cause of mortality
(100,000/year)
• Only major health problem for which
mortality has been increasing for past
20 years
• Results in 500,000 hospitalizations/year
• Second leading cause of missed work
days
29. COPD - Diagnosis
• Symptoms
• chronic cough - intermittent, nonproductive
• cough with sputum production, ‘smoker’s cough’
• dyspnea on exertion, usually progressive and indolent
(slow advancing)
• Spirometry
• Should spirometry screening be performed on the general
population?
• No, but in those with higher risk - i.e. all current and
former smokers over the age of 40 years with any of
the above symptoms of disease
30. The Importance of Screening for
COPD
• The Rule of 50s
• 50% of COPD patients are
undiagnosed (or approximately 12 million
patients in U.S.)
• COPD is evident by age 50
• At time of diagnosis, FEV1 is <50%
predicted
• 50% 5-year survival rate
31. COPD Staging
• Based upon the GOLD Guidelines
• Classified into 4 stages
• Staging is based primarily upon FEV1:
• FEV1 < 80%
• FEV1:FVC < 70% more severe the
disease
• The lower the FEV1 the classification.
33. COPD Management and Therapies
• Vaccination - pneumococcal (i.m.) and influenza (s.c.)
• Regular Assessment of lung function - annually
• Cessation of tobacco use
• Drug Therapy:
• short acting (SABA) vs. long acting bronchodilators
(LABA)
• inhaled (ICS) vs. oral corticosteroids (systemic steroids)
34. COPD - Management of Stable Disease
• Smoking cessation: rate of FEV1 deterioration
will slow to near normal (20 ml /yr vs. 65 ml
/yr for active smokers) if patient stops smoking
35. COPD - Drug Therapy
• Therapy recommendations based on their effect on FEV1.
• First Line therapy:
• Beta agonists - short (SABA) and long acting (LABA)
• Anticholinergics - short (SAMA) and long acting (LAMA)
• Second Line therapy:
• Steroids - inhaled (ICS) vs. oral (systemic steroids)
• Supplemental therapies
36. Beta agonists
• Mechanism of Action -
bronchodilate by
stimulating Beta-2
receptors
• Studies show that COPD
patients do not
develop tolerance to
short acting or long
acting beta agonists
• Asthmatics tend to
develop tolerance to
short acting agonists
• Can Salmeterol be used
as monotherapy?
Drug Albuterol Salmeterol
Onset 1 to 3 min 20 min
Duration 4 to 6 hrs 12+ hrs
YES, salmeterol monotherapy had
adverse outcomes in asthma study, note
COPD.
37. Anticholinergics
• Mechanism of action-
bronchodilation by
decreasing airway
smooth muscle tone
• Also reduces
sputum production
• Combination of an
anticholinergic +
β2-agonist produces
greater and more
sustained rise in
FEV1 than either
drug alone.
Drug
Ipratropiu
m
Tiotropium
Onset 20 min ?
Duration 4 to 8 hrs 24 hrs
Selectivity
All
Muscarinic
M1 and M3>
M2
38. Tiotropium (Spiriva)
• Studies show that once
daily tiotropium has
resulted in a lasting increase
in FEV1 out to one year.
• 174 ml above baseline
in good short-term
responders
• 56 ml increase in
poor short-term
responders
Special delivery device.
39. Inhaled Corticosteroids (ICS)
• Have not been shown to slow the progression of
disease or provide long term benefit
• ISOLDE trial - patients with FEV1 of 50%
predicted value had a 25% reduction of
exacerbations
• Combination with salmeterol more effective in
reducing exacerbations than either drug alone
• Unfortunately, recently published trial failed to
demonstrate statistically significant reduction in
mortality with salmeterol/fluticasone combo.
40. New COPD Treatment Data
• compared salmeterol/fluticasone head to
head with tiotropium
• No difference in exacerbation rate
although more in tiotropium group had
higher drop out rate.
• More patients in salmeterol/fluticasone
developed pneumonia.
41. Oral Corticosteroids
• They have no proven benefit in stable
COPD
• Oral steroids are useful for acute
exacerbations
• What is the recommended duration of
therapy?
• Maximum benefit obtained during
first 2 weeks of therapy.
42. Supplemental Therapies
• Supplemental oxygen for hypoxemia (worn
for more than 15 hrs/day) has been shown to
reduce moratality
• What are the qualification parameters
for oxygen therapy?
• PaO2 of 55mmHg or less, or pulse
oximetry of 88% or less
• Pulmonary Rehabilitation
• Lung reduction and lung transplantation
surgeries
44. Summary
• Early diagnosis, disease prevention, smoking
cessation and vaccination are important.
• Initiate bronchodilator therapy early in disease
course, combination of albuterol with ipratropium most
effective
• Inhaled corticosteroids may be useful in patients
with severe disease or with objective responses on
spirometry.
• Will likely see inflammatory modulators (TNF-
α) in the future